HKSE - Delayed Quote HKD

Giant Biogene Holding Co., Ltd. (2367.HK)

Compare
52.500
+0.800
+(1.55%)
As of 11:59:28 AM GMT+8. Market Open.
Loading Chart for 2367.HK
DELL
  • Previous Close 51.700
  • Open 51.700
  • Bid 52.400 x --
  • Ask 52.500 x --
  • Day's Range 51.150 - 52.550
  • 52 Week Range 28.750 - 58.000
  • Volume 1,373,349
  • Avg. Volume 3,237,385
  • Market Cap (intraday) 53.28B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) 27.63
  • EPS (TTM) 1.900
  • Earnings Date --
  • Forward Dividend & Yield 0.48 (0.93%)
  • Ex-Dividend Date Jun 17, 2024
  • 1y Target Est 61.82

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, and SKIGIN brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

www.xajuzi.com

1,512

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2367.HK

View More

Performance Overview: 2367.HK

Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

2367.HK
6.49%
HANG SENG INDEX
3.88%

1-Year Return

2367.HK
49.41%
HANG SENG INDEX
18.59%

3-Year Return

2367.HK
101.92%
HANG SENG INDEX
20.99%

5-Year Return

2367.HK
101.92%
HANG SENG INDEX
33.31%

Compare To: 2367.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2367.HK

View More

Valuation Measures

As of 1/14/2025
  • Market Cap

    52.47B

  • Enterprise Value

    46.03B

  • Trailing P/E

    27.20

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.77

  • Price/Book (mrq)

    8.28

  • Enterprise Value/Revenue

    9.72

  • Enterprise Value/EBITDA

    20.04

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    39.65%

  • Return on Assets (ttm)

    21.27%

  • Return on Equity (ttm)

    37.14%

  • Revenue (ttm)

    4.46B

  • Net Income Avi to Common (ttm)

    1.77B

  • Diluted EPS (ttm)

    1.900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.06B

  • Total Debt/Equity (mrq)

    0.02%

  • Levered Free Cash Flow (ttm)

    2.28B

Research Analysis: 2367.HK

View More

People Also Watch